Alisertib (MLN8237)

For research use only. Not for use in humans.

目录号：S1133 中文名称：阿利色替

CAS No. 1028486-01-2

Alisertib (MLN8237)是一种选择性Aurora A抑制剂，无细胞试验中IC50为1.2 nM，作用于Aurora A比作用于Aurora B选择性强200倍以上。Alisertib 可诱导细胞周期阻滞、细胞凋亡与自噬。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1375.12	现货
5mg	RMB 983.87	现货
10mg	RMB 1725.78	现货
50mg	RMB 5505.84	现货
200mg	RMB 14496.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Alisertib (MLN8237)发表文献277篇：

Cancer Cell, 2021, S1535-6108(21)00383-4

PubMed: 34388376 ( click the link to review the publication )

Cancer Cell, 2021, S1535-6108(21)00492-X

PubMed: 34624218 ( click the link to review the publication )

Cancer Cell, 2021, S1535-6108(21)00338-X

PubMed: 34270926 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nature, 2019, 574(7777):268-272

PubMed: 31578521 ( click the link to review the publication )

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nat Med, 2016, 22(7):744-53

PubMed: 27213815 ( click the link to review the publication )

Cancer Cell, 2014, 26(3):414-427

PubMed: 25175806 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Nat Commun, 2021, 12(1):4789

PubMed: 34373451 ( click the link to review the publication )

Nat Commun, 2021, 12(1):5203

PubMed: 34471141 ( click the link to review the publication )

EMBO Rep, 2021, e51902

PubMed: 34169630 ( click the link to review the publication )

Cancer Res, 2021, canres.2811.2020

PubMed: 34247147 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

Cell Death Dis, 2021, 12(9):821

PubMed: 34462431 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00400-1

PubMed: 34525344 ( click the link to review the publication )

PLoS Genet, 2021, 17(4):e1009327

PubMed: 33901174 ( click the link to review the publication )

Neoplasia, 2021, 23(6):624-633

PubMed: 34107377 ( click the link to review the publication )

Am J Cancer Res, 2021, 11(6):3240-3251

PubMed: 34249458 ( click the link to review the publication )

Sci Rep, 2021, 11(1):20338

PubMed: 34645858 ( click the link to review the publication )
Sci Rep, 2021, 11(1):19138

PubMed: 34580349 ( click the link to review the publication )

Sci Rep, 2021, 11(1):10461

PubMed: 34002003 ( click the link to review the publication )

Mol Pharmacol, 2021, 99(6):435-447

PubMed: 33795352 ( click the link to review the publication )

J Nat Prod, 2021, 84(8):2312-2320

PubMed: 34406008 ( click the link to review the publication )

Cancer Commun (Lond), 2021, 10.1002/cac2.12125

PubMed: 33471959 ( click the link to review the publication )

Cancer Commun (Lond), 2021, 10.1002/cac2.12190

PubMed: 34251762 ( click the link to review the publication )

Mol Cell Endocrinol, 2021, 528:111243

PubMed: 33716050 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01019-9

PubMed: 33409897 ( click the link to review the publication )

Biomed Res Int, 2021, 2021:6613439

PubMed: 34337035 ( click the link to review the publication )

Int J Med Sci, 2021, 18(15):3437-3451

PubMed: 34522170 ( click the link to review the publication )

Sci Rep, 2021, 11(1):2616

PubMed: 33510346 ( click the link to review the publication )

EMBO Rep, 2021, e51030

PubMed: 33615693 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

J Clin Invest, 2020, 139080

PubMed: 33016928 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Oncogene, 2020, 16

PubMed: 32300176 ( click the link to review the publication )

Cancer Lett, 2020, 495:135-144

PubMed: 32979462 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2498

PubMed: 32899210 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32235770 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(10):3406-3414

PubMed: 33163279 ( click the link to review the publication )

Mol Cancer Res, 2020, 8

PubMed: 32269073 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.1226.2019

PubMed: 32591441 ( click the link to review the publication )
Front Oncol, 2020, 10:1354

PubMed: 32974133 ( click the link to review the publication )

J Cell Sci, 2020, 133(24)jcs240267

PubMed: 33376154 ( click the link to review the publication )

Dis Model Mech, 2020, dmm.44289

PubMed: 32571902 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15901

PubMed: 32954665 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(18)E6690

PubMed: 32932728 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Cancer Res, 2020, 80(16):3424-3435

PubMed: 32595135 ( click the link to review the publication )

J Cancer, 2020, 11(8):2241-2251

PubMed: 32127951 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:857

PubMed: 33042987 ( click the link to review the publication )

Cancer Lett, 2020, 491:50-59

PubMed: 32735909 ( click the link to review the publication )

CU Digital Repository, 2020, N/A

PubMed: N/A ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa570

PubMed: 32652013 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3485

PubMed: 31375684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5566

PubMed: 31804482 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2208

PubMed: 31101817 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(14):4552-4566

PubMed: 30979745 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3430-3442

PubMed: 30755439 ( click the link to review the publication )

Dev Cell, 2019, 50(3):355-366e6

PubMed: 31303441 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Rep, 2019, 26(2):293-301e7

PubMed: 30625311 ( click the link to review the publication )

Oncogene, 2019, 38(1):73-87

PubMed: 30082913 ( click the link to review the publication )
EBioMedicine, 2019, 41:120-133

PubMed: 30799199 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):881

PubMed: 31754113 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):606

PubMed: 31406104 ( click the link to review the publication )

FASEB J, 2019, 33(4):4866-4882

PubMed: 30596512 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.003

PubMed: 31257184 ( click the link to review the publication )

Curr Biol, 2019, 29(21):3563-3578

PubMed: 31668617 ( click the link to review the publication )

PLoS Negl Trop Dis, 2019, 13(5):e0007425

PubMed: 31095613 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(3):312-323

PubMed: 30485161 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2211

PubMed: 30778113 ( click the link to review the publication )

Int J Oncol, 2019, 55(4):938-948

PubMed: 31485600 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

J Pediatr Hematol Oncol, 2019, 41(6):e359-e370

PubMed: 30702467 ( click the link to review the publication )

Target Oncol, 2019, 14(5):563-575

PubMed: 31429028 ( click the link to review the publication )

Oncotarget, 2019, 10(17):1649-1659

PubMed: 30899434 ( click the link to review the publication )

Oncogene, 2019, 38(40):6696-6710

PubMed: 31391550 ( click the link to review the publication )

Blood Adv, 2019, 3(21):3214-3227

PubMed: 31698452 ( click the link to review the publication )

J Vis Exp, 2019, (151)

PubMed: 31589210 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Curr Biol, 2018, 28(21):3458-3468e5

PubMed: 30415701 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(24):6594-6610

PubMed: 30181387 ( click the link to review the publication )

J Cell Biol, 2018, 217(1):107-116

PubMed: 29074706 ( click the link to review the publication )

J Cell Biol, 2018, 217(2):483-493

PubMed: 29222185 ( click the link to review the publication )

Elife, 2018, doi: 107554/eLife38111

PubMed: 30070631 ( click the link to review the publication )

Thyroid, 2018, doi: 101089/thy20180183

PubMed: 30226440 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )

Oncogene, 2018, 37(22):2921-2935

PubMed: 29515234 ( click the link to review the publication )

Oncogene, 2018, 37(4):502-511

PubMed: 28967900 ( click the link to review the publication )

BMC Biol, 2018, 16(1):116

PubMed: 30336771 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):781

PubMed: 30013101 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2575-2585

PubMed: 30266802 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

Pharmacol Res, 2018, 134:166-178

PubMed: 29944980 ( click the link to review the publication )

Mol Pharm, 2018, 15(8):3046-3059

PubMed: 29863884 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30544932 ( click the link to review the publication )

Apoptosis, 2018, 23(9-10):492-511

PubMed: 30027525 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):652-668

PubMed: 28749250 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )

J Cancer, 2018, 9(12):2061-2071

PubMed: 29937924 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )

Int J Mol Med, 2018, 41(6):3629-3641

PubMed: 29512701 ( click the link to review the publication )

Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):1206-1210

PubMed: 29845253 ( click the link to review the publication )
Anticancer Res, 2018, 38(6):3471-3476

PubMed: 29848699 ( click the link to review the publication )

Oncotarget, 2018, 9(89):35875-35890

PubMed: 30542505 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14017

PubMed: 30228302 ( click the link to review the publication )

Oncotarget, 2018, 9(16):12769-12780

PubMed: 29560108 ( click the link to review the publication )

SLAS Discov, 2018, 23(8):850-861

PubMed: 29742358 ( click the link to review the publication )

J Neurooncol, 2018, 137(3):481-492

PubMed: 29396807 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29560108 ( click the link to review the publication )

R Soc Open Sci, 2018, 5(12):181303

PubMed: 30662739 ( click the link to review the publication )

Sci Transl Med, 2017, 9(372)

PubMed: 28077684 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8:14294

PubMed: 28220783 ( click the link to review the publication )

Clin Cancer Res, 2017, 10.1158/1078-0432

PubMed: 28073841 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3571-3590

PubMed: 28972102 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 27593935 ( click the link to review the publication )

EBioMedicine, 2017, 24:43-55

PubMed: 29030058 ( click the link to review the publication )

Plant Physiol, 2017, 173(1):582-599

PubMed: 27879390 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(1):94-107

PubMed: 28848145 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28615297 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2552-2562

PubMed: 28847989 ( click the link to review the publication )

Eur J Med Chem, 2017, 140:1-19

PubMed: 28918096 ( click the link to review the publication )
Cell Discov, 2017, 3:16049

PubMed: 28101375 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(6):670-682

PubMed: 28235899 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(8):984-997

PubMed: 28442587 ( click the link to review the publication )

J Cell Sci, 2017, 130(4):683-688

PubMed: 28069833 ( click the link to review the publication )

Cell Discov, 2017, 3:16049

PubMed: 28101375 ( click the link to review the publication )

Sci Rep, 2017, 7:45514

PubMed: 28358124 ( click the link to review the publication )

J Biol Chem, 2017, 292(5):1910-1924

PubMed: 28028179 ( click the link to review the publication )

Am J Transl Res, 2017, 9(10):4652-4672

PubMed: 29118925 ( click the link to review the publication )

Am J Transl Res, 2017, 9(3):845-873

PubMed: 28386317 ( click the link to review the publication )

BMC Cell Biol, 2017, 18(1):33

PubMed: 29141582 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(4):386-401

PubMed: 27396604 ( click the link to review the publication )

Oncotarget, 2017, 8(10):16669-16689

PubMed: 28035071 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(19):32117-32133

PubMed: 28389630 ( click the link to review the publication )

Sci Rep, 2017, 7(1):17978

PubMed: 29269934 ( click the link to review the publication )

Sci Rep, 2017, 7:45514

PubMed: 28358124 ( click the link to review the publication )

Oncotarget, 2017, 8(68):112313-112329

PubMed: 29348827 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19738-19759

PubMed: 28160569 ( click the link to review the publication )

Oncotarget, 2017, 8(41):69691-69708

PubMed: 29050234 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017, 8(59):100326-100338

PubMed: 29245981 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114474-114480

PubMed: 29383095 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19478-19490

PubMed: 28061448 ( click the link to review the publication )

Oncotarget, 2017, 8(54):92926-92942

PubMed: 29190967 ( click the link to review the publication )
Pharmaceuticals (Basel), 2017, 10(3)

PubMed: 29036881 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(19):32117-32133

PubMed: 28389630 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Nat Commun, 2016, 7:10180

PubMed: 26782714 ( click the link to review the publication )

Nat Commun, 2016, 7:11389

PubMed: 27091106 ( click the link to review the publication )

Nat Commun, 2016, 7:12674

PubMed: 27624869 ( click the link to review the publication )

Elife, 2016, 5:e10877

PubMed: 26880562 ( click the link to review the publication )

Elife, 2016, 5:e11402

PubMed: 26878753 ( click the link to review the publication )

J Med Chem, 2016, 59(15):7188-211

PubMed: 27391133 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2135

PubMed: 26962685 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(8):1574-87

PubMed: 26908596 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(12):3400-3411

PubMed: 27768280 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Cell Biochem, 2016, 117(6):1340-51

PubMed: 26529125 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):566-76

PubMed: 27082306 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):413-24

PubMed: 26713495 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:3473-84

PubMed: 27366084 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 475(3):251-6

PubMed: 27233613 ( click the link to review the publication )

Exp Hematol, 2016, 44(4):247-56

PubMed: 26724640 ( click the link to review the publication )

Mol Med Rep, 2016, 14(1):394-8

PubMed: 27177156 ( click the link to review the publication )

Biol Bull, 2016, 231(1):61-72

PubMed: 27638695 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58435-58444

PubMed: 27533080 ( click the link to review the publication )
Oncotarget, 2016, 7(22):33152-64

PubMed: 27121204 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84718-84735

PubMed: 27713168 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

J Cell Biol, 2015, 210(1):45-62

PubMed: 26124292 ( click the link to review the publication )

Mol Cancer, 2015, 14(1):83

PubMed: 25889801 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(9):2292-2300

PubMed: 25848977 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: 25395580 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):527-40

PubMed: 25501809 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):516-26

PubMed: 25501815 ( click the link to review the publication )

J Cell Sci, 2015, 128(20):3769-80

PubMed: 26349807 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):527-40

PubMed: 25501809 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: ( click the link to review the publication )

J Cell Sci, 2015, 128(20):3769-80

PubMed: 26349807 ( click the link to review the publication )

Int J Mol Sci, 2015,

PubMed: 26729093 ( click the link to review the publication )

Breast Cancer Res Tr, 2015, 149(3):715-26

PubMed: 25667100 ( click the link to review the publication )

Cell Cycle, 2015, 14(24):3908-19

PubMed: 26697841 ( click the link to review the publication )

Cell Cycle, 2015, 14(9):1447-58

PubMed: 25789545 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:1555-84

PubMed: 25792811 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:575-601

PubMed: 25632225 ( click the link to review the publication )

BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )
Oncotarget, 2015, 6(34):35247-62

PubMed: 26497213 ( click the link to review the publication )

Clin Cancer Res, 2014, 34(5):2269-74

PubMed: 24778030 ( click the link to review the publication )

Oncogene, 2014, 33(42):4985-96

PubMed: 24166501 ( click the link to review the publication )

Oncogene, 2014, 33(27):3550-60

PubMed: 23955083 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1253

PubMed: 24853431 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(5):797-811

PubMed: 25074669 ( click the link to review the publication )

Mol Oncol, 2014, 8(8):1419-28

PubMed: 24953013 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2719-2729

PubMed: 25090971 ( click the link to review the publication )

J Transl Med, 2014, 12(1):200

PubMed: 25082261 ( click the link to review the publication )

Mol Carcinog, 2014, 10.1002/mc.22223

PubMed: 25284017 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

FEBS Lett, 2014, 588(14):2198-205

PubMed: 24857377 ( click the link to review the publication )

Chembiochem, 2014, 15(3):443-50

PubMed: 24403173 ( click the link to review the publication )

PLoS One, 2014, 9(12):e113989

PubMed: 25436453 ( click the link to review the publication )

PLoS One, 2014, 9(3):e92402

PubMed: 24642638 ( click the link to review the publication )

PLoS One, 2014, 9(12):e116048

PubMed: 25545367 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101222

PubMed: 24983972 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

PLoS One, 2014,

PubMed: ( click the link to review the publication )
Biochem Biophys Res Commun, 2014, 452(3):845-51

PubMed: 25218503 ( click the link to review the publication )

Neurosci Lett, 2014, 583:199-204

PubMed: 25263789 ( click the link to review the publication )

J Pediatr Surg, 2014, 49(1):159-65

PubMed: 24439602 ( click the link to review the publication )

Oncotarget, 2014, 5(10):2947-61

PubMed: 24930769 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4071-86

PubMed: 24901229 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6229-42

PubMed: 25153724 ( click the link to review the publication )

Nat Commun, 2013, 4:2656

PubMed: 24141283 ( click the link to review the publication )

EMBO Mol Med, 2013, 5(1):149-66

PubMed: 23180582 ( click the link to review the publication )

Leukemia, 2013, 27(3):560-8

PubMed: 22940834 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(19):E1779-87

PubMed: 23610398 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

J Cell Biol, 2013, 202(3):463-78

PubMed: 23918938 ( click the link to review the publication )

EMBO Rep, 2013, 14(9):829-36

PubMed: 23887685 ( click the link to review the publication )

Int J Cancer, 2013, 135(3):751-62

PubMed: 24382688 ( click the link to review the publication )

Oral Oncol, 2013, 49(6):551-9

PubMed: 23481312 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(7):1451-9

PubMed: 23597309 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 6):1355-65

PubMed: 23345402 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 9):2102-13

PubMed: 23532825 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1833(10):2220-32

PubMed: 23707954 ( click the link to review the publication )

Epigenetics Chromatin, 2013, 6(1):21

PubMed: 23829974 ( click the link to review the publication )

J Biol Chem, 2013, 289(1):74-88

PubMed: 24273164 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64306

PubMed: 23717592 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )
Oncotarget, 2013,

PubMed: 23328114 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27670-81

PubMed: 22753416 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 135(2):433-44

PubMed: 22825030 ( click the link to review the publication )

Cell Cycle, 2012, 11(2):296-309

PubMed: 22214762 ( click the link to review the publication )

Cell Cycle, 2012, 11(13):2567-77

PubMed: 22722494 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30734

PubMed: 22359551 ( click the link to review the publication )

EMBO J, 2011, 30(5):906-19

PubMed: 21297582 ( click the link to review the publication )

Mol Cancer, 2011, 10:131

PubMed: 22011530 ( click the link to review the publication )

Oncotarget, 2011,

PubMed: 21865609 ( click the link to review the publication )

J Cell Biol, 2010, 191(7):1315-32

PubMed: 21187329 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):977-84

PubMed: 21072059 ( click the link to review the publication )

ACS Chem Biol, 2010, 5(6):563-76

PubMed: 20426425 ( click the link to review the publication )

Expert Opin Emerg Dr, 2010, 15(4):615-34

PubMed: 20690888 ( click the link to review the publication )

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述

特性

MLN8237 是第一个口服有效的小分子Aurora A激酶选择性抑制剂。

靶点

Aurora A ^[1]
(Cell-free assay)

1.2 nM

体外研究

MLN8237作用于Aurora A选择性比作用于结构相关的Aurora B 高200多倍，IC50为396.5 nM, 而对205种其他激酶则没有显著活性。^[1] 0.5 μM MLN8237处理MM1.S和 OPM1 细胞，抑制 Aurora A磷酸化，而不影响 Aurora B调节的组蛋白H3磷酸化。MLN8237作用于多发性骨髓瘤(MM) 细胞系，显著抑制细胞增殖，IC50为0.003-1.71 μM。在BM 基质细胞，IL-6和 IGF-1 存在时，MLN8237作用于原代MM 细胞和MM细胞系，抗增殖活性比只有MLN8237单独作用时高很多。0.5 μM MLN8237 作用于原代MM细胞和细胞系，使G2/M 期细胞提高2到6倍，且显著诱导凋亡和衰老，涉及p53, p21 和p27的上调,及 PARP,caspase 3,和 caspase 9的裂解。此外, MLN8237和 Dexamethasone联用具有协同作用，具有强抗MM 功效, 而和Doxorubicin 及Bortezomib联用则具有另外的功能。^[2] 0.5 μM MLN8237处理 FLO-1, OE19, 和OE33 食管腺癌细胞系，抑制集落形成，且显著提高多倍体细胞百分数,随后提高G1期细胞百分数,而与 Cisplatin (2.5 μM)联用则效果进一步提高，与单独用药相比，诱导产生更多, TAp73β, PUMA, NOXA, cleaved caspase-3, 和cleaved PARP。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT116	MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\WNE42KM7:TR?=	MV[3NkBp	NFW0cW9FVVOR	M3zpb2lEPTB;MD6wOEDPxE1?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|Nk[4OEc,OjZzM{[2PFQ9N2F-
LS174T	NVHlPXNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjLfll6OC53IN88US=>	Ml7nO\|IhcA>?	MlvFSG1UVw>?	NVroUmlNUUN3ME2wMlA2KM7:TR?=	NH[2Vpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlY5PCd-Mk[xN\|Y3QDR:L3G+
T84	NIHpUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\1bVJSOC53IN88US=>	NGPGNG44OiCq	NGLuVVVFVVOR	NGflVnJKSzVyPUCuNFkh\|ryP	MlnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[2PFQoRjJ4MUO2Olg1RC:jPh?=
LS180	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NESxS4YxNjVizszN	MXy3NkBp	NE\ZcG1FVVOR	NGT4[\|dKSzVyPUGg{txO	M{PYXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2Olg1Lz5{NkGzOlY5PDxxYU6=
SW948	NXvaRok5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE[2c4kxNjVizszN	NUnMXmNTPzJiaB?=	NF;YbXFFVVOR	NGjWVGdKSzVyPUGg{txO	NYq3Nph{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|Y3QDRpPkK2NVM3Pjh2PD;hQi=>
HCT15	NX\XSFRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rqTlAvPSEQvF2=	NGH3[lc4OiCq	M1HMZmROW09?	MkDlTWM2ODxyLkSg{txO	MkmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[2PFQoRjJ4MUO2Olg1RC:jPh?=
DLD-1	NVy3Xo81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnONE42KM7:TR?=	MX[3NkBp	MX7EUXNQ	MYLJR\|UxRDBwODFOwG0>	M1PudVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO2Olg1Lz5{NkGzOlY5PDxxYU6=
MIP-101	Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjmSHAxNjVizszN	NVfte2JNPzJiaB?=	MWfEUXNQ	NV7FUJY6UUN3ME2xJO69VQ>?	NF;r[3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlY5PCd-Mk[xN\|Y3QDR:L3G+
SNU1544	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrjdWoxNjVizszN	NX7wUGFnPzJiaB?=	NEm3T3ZFVVOR	MnmzTWM2OD1zIN88US=>	NY[3R3pZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|Y3QDRpPkK2NVM3Pjh2PD;hQi=>
OCI-Ly10	MYrDfZRwfG:6aXOgRZN{[Xl?		M2DzbFczKGh?	MnG1SG1UVw>?	NYrSV2gxUUN3ME2wMlA2QCEQvF2=	Mmf2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{izN\|EoRjJ3OEe4N\|MyRC:jPh?=
SU-DHL2	NX;FeZp1S3m2b4TvfIlkKEG\|c3H5		NFTHTnE4OiCq	NHXwXGpFVVOR	MmWyTWM2OD1yLkCxJO69VQ>?	MoLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{izN\|EoRjJ3OEe4N\|MyRC:jPh?=
OCI-LY7	MVzDfZRwfG:6aXOgRZN{[Xl?		MV:3NkBp	NGjoOIZFVVOR	MmrHTWM2OD1yLkC4NUDPxE1?	MnXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{izN\|EoRjJ3OEe4N\|MyRC:jPh?=
SU-DHL6	Ml\DR5l1d3SxeHnjJGF{e2G7		NH73VYs4OiCq	Mn;wSG1UVw>?	M4S5S2lEPTB;MD60PFIh\|ryP	Mnv5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{izN\|EoRjJ3OEe4N\|MyRC:jPh?=
Jeko-1	NXHuZXZzS3m2b4TvfIlkKEG\|c3H5		MlrZO\|IhcA>?	MUDEUXNQ	MU\JR\|UxRTBwMEK5JO69VQ>?	Ml3kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{izN\|EoRjJ3OEe4N\|MyRC:jPh?=
JVM-2	MmS3R5l1d3SxeHnjJGF{e2G7		MXq3NkBp	MV;EUXNQ	MUTJR\|UxRTBwMEGg{txO	NWHLXG1URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
Rec-1	NE\4codEgXSxdH;4bYMhSXO\|YYm=		NYnhdYZNPzJiaB?=	NXjxeIN[TE2VTx?=	NWPnPZVoUUN3ME2wMlA5PyEQvF2=	MonqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{izN\|EoRjJ3OEe4N\|MyRC:jPh?=
Z-138	NV;yOWtRS3m2b4TvfIlkKEG\|c3H5		MmTKO\|IhcA>?	NF7s[W9FVVOR	MkjrTWM2OD1yLkCxN{DPxE1?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
H9	M{n4RWN6fG:2b4jpZ{BCe3OjeR?=		MVy3NkBp	MlLvSG1UVw>?	NHvXbZZKSzVyPUCuOkDPxE1?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
HH	MX3DfZRwfG:6aXOgRZN{[Xl?		NV\UOJZmPzJiaB?=	MoG2SG1UVw>?	M4\RfGlEPTB;MD63JO69VQ>?	NH\K[JQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3PFM{OSd-MkW4O\|g{OzF:L3G+
DND41	M4jZN2N6fG:2b4jpZ{BCe3OjeR?=		MWK3NkBp	MUXEUXNQ	NX;rO5hOUUN3ME2wMlEh\|ryP	MnfXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{izN\|EoRjJ3OEe4N\|MyRC:jPh?=
CCL119	MnnSR5l1d3SxeHnjJGF{e2G7		NW\Pd\|Y4PzJiaB?=	NYPa[HlTTE2VTx?=	MVTJR\|UxRTBwME[yJO69VQ>?	NF\lOHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3PFM{OSd-MkW4O\|g{OzF:L3G+
J.Cam 1.6	MWHDfZRwfG:6aXOgRZN{[Xl?		MmjPO\|IhcA>?	NYr4NolITE2VTx?=	M1fLTGlEPTB;MD6xNFUh\|ryP	NUnVZ2N5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
Sup-T1	NIL2N5hEgXSxdH;4bYMhSXO\|YYm=		MlnaO\|IhcA>?	NWKwVFB{TE2VTx?=	NXrFdnhtUUN3ME2yMlE1OiEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
Tib 152	MoLpR5l1d3SxeHnjJGF{e2G7		MVy3NkBp	NYjPb2Y5TE2VTx?=	MljSTWM2OD1yLkig{txO	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
MCF7	NHTU[lZHfW6ldHnvckBCe3OjeR?=	M3rmclUh\|ryP	MUCyOEBp	MXrEUXNQ	M1TTbGlv\HWlZYOgS\|IwVSCjcoLld5Q>	NF\rZW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MDA-MB-231	NHXJXnBHfW6ldHnvckBCe3OjeR?=	M2HyUFUh\|ryP	M1zsS\|I1KGh?	NYrPNlZmTE2VTx?=	MVrJcoR2[2W\|IFezM20h[XK{ZYP0	NV\hOINWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MCF7	MonXSpVv[3Srb36gRZN{[Xl?	NF\kdpA2KM7:TR?=	M{H1Z\|I1KGh?	M1zzbWROW09?	NEPaXI9F\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy	M1[2WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MCF7	MYHGeY5kfGmxbjDBd5NigQ>?	MXu1JO69VQ>?	MkO2NlQhcA>?	M4LjUmROW09?	NHLBXoxF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOg>?	NUXuO\|BvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MCF7	MXnGeY5kfGmxbjDBd5NigQ>?	NXLuc5hnPSEQvF2=	Mm\ZNlQhcA>?	MUnEUXNQ	NETEVGJF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MCF7	M2nKTWZ2dmO2aX;uJGF{e2G7	MYi1JO69VQ>?	MWmyOEBp	NV7Z[\|NrTE2VTx?=	MoPXTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE>	M{C3Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MCF7	MXjGeY5kfGmxbjDBd5NigQ>?	M{jJfVUh\|ryP	NHrSS4szPCCq	NXXPTJdZTE2VTx?=	NX3vTZBLUW6lcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJJAzPyCNaYCx	MmSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MDA-MB-231	NGTYUY1HfW6ldHnvckBCe3OjeR?=	M1\Le\|Uh\|ryP	NFq2bWMzPCCq	NUfMSWhyTE2VTx?=	M1O4TWRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsyN0OGQ{K=	MlrkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MDA-MB-231	NELXbVdHfW6ldHnvckBCe3OjeR?=	MmHDNUDPxE1?	M3PkW\|I1KGh?	MXPEUXNQ	NVvhcJJrUW6lcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJGNFUzJ?	NYS1WnpURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MDA-MB-231	NFLyNllHfW6ldHnvckBCe3OjeR?=	NXfpVXZYPSEQvF2=	M{\xd\|I1KGh?	M3vDeWROW09?	NVjCOGVyTGWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJIN6[2yrbjDCNS=>	NXzJdVdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MDA-MB-231	MWnGeY5kfGmxbjDBd5NigQ>?	MUC1JO69VQ>?	MWGyOEBp	NFXETHVFVVOR	MmrKTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE>	M2HvZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MDA-MB-231	MXfGeY5kfGmxbjDBd5NigQ>?	MV:1JO69VQ>?	M2DEeFI1KGh?	MWfEUXNQ	MXvJcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEK3JGtqeDF?	NFPvTHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MDA-MB-231	MV\GeY5kfGmxbjDBd5NigQ>?	NGjDZ\|E2KM7:TR?=	M2fjcFI1KGh?	MXHEUXNQ	Mnu3TY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIIC1Ny=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MCF7	NEPzO5RCeG:ydH;zbZMhSXO\|YYm=	NEXkTJQ2KM7:TR?=	MX[yOEBp	MknkSG1UVw>?	MmHvTY5lfWOnczDhdI9xfG:2aXOg[IVifGh?	M3jNfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MDA-MB-231	NUOwfnNzSXCxcITvd4l{KEG\|c3H5	M3;IV\|Uh\|ryP	NX3GSlVuOjRiaB?=	Mn7NSG1UVw>?	NFTKO3JKdmS3Y3XzJIFxd3C2b4TpZ{Bl\WG2aB?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MCF7	NYrvXYN3TnWwY4Tpc44hSXO\|YYm=	NXnhc4tlOSEQvF2=	NF;PNoI4OiCq	M3nvWmROW09?	MX3JcoR2[2W\|IHH1eI9xcGGpaXOg[IVifGh?	Mn;3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MDA-MB-231	NULVbpdxTnWwY4Tpc44hSXO\|YYm=	NIm3SVcyKM7:TR?=	MUG3NkBp	MkHqSG1UVw>?	M3;5U2lv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?=	M4i1fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
U-2 OS	MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHm0PWI2OCEQvF2=	NXnPWIZPOjRiaB?=	NX;pO495TE2VTx?=	M1q3UWlEPTB;MU[uOkDPxE1?	NXHnXoRMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVI5OTFpPkK1O\|kzQDFzPD;hQi=>
MG-63	MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLWOVAh\|ryP	NX;uRpBoOjRiaB?=	M1y3XmROW09?	NYDlRW12UUN3ME25MlUh\|ryP	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7MkixNUc,OjV5OUK4NVE9N2F-
U-2 OS	NXvYWZg6SXCxcITvd4l{KEG\|c3H5	NGDZT5I2KM7:TR?=	NIG4bWEzPCCq	M{W5VmROW09?	MUHJcoR2[2W\|IHHwc5B1d3SrYzDj[YxtKGSnYYTo	M1zOeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{myPFEyLz5{NUe5NlgyOTxxYU6=
MG-63	MlLkRZBweHSxc3nzJGF{e2G7	NGG2fFA2KM7:TR?=	MX[yOEBp	NIW1OVRFVVOR	NFvDPHNKdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp	MlTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUK4NVEoRjJ3N{myPFEyRC:jPh?=
U-2 OS	MVXGeY5kfGmxbjDBd5NigQ>?	M1\ufFUh\|ryP	MnrxNlQhcA>?	MkTHSG1UVw>?	MkHZVJJwdW:2ZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7MkixNUc,OjV5OUK4NVE9N2F-
MG-63	NWPmZpQ{TnWwY4Tpc44hSXO\|YYm=	NHXvTnY2KM7:TR?=	MkXKNlQhcA>?	Ml\WSG1UVw>?	NWX1RYRkWHKxbX;0[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7MkixNUc,OjV5OUK4NVE9N2F-
PANC-1	NV3qZoVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXrZYtJPTBizszN	NUDscoV7OjRiaB?=	M{XaN2ROW09?	NFPLbo5KSzVyPUeuNUDPxE1?	M37V[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkOyNlI2Lz5{NU[zNlIzPTxxYU6=
BxPC-3	NGP6RVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfweGE2OCEQvF2=	MmPoNlQhcA>?	Mle1SG1UVw>?	MoSwTWM2OD14Lkig{txO	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ\|MkKyOUc,OjV4M{KyNlU9N2F-
PANC-1	NGG2RXBHfW6ldHnvckBCe3OjeR?=	NEHXcYY2KM7:TR?=	NUeyVG1{OjRiaB?=	M4TmRWROW09?	MX\JcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U>	NV61Nld4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|IzOjVpPkK1OlMzOjJ3PD;hQi=>
BxPC-3	MVPGeY5kfGmxbjDBd5NigQ>?	MVW1JO69VQ>?	NFzOXHEzPCCq	MYLEUXNQ	NVLIU2VjUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn	NFHMOlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zNlIzPSd-MkW2N\|IzOjV:L3G+
PANC-1	MXXGeY5kfGmxbjDBd5NigQ>?	MUG1JO69VQ>?	MkfhNlQhcA>?	M{faRmROW09?	NIrFdmJKdmS3Y3XzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>?	NVzKVo46RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|IzOjVpPkK1OlMzOjJ3PD;hQi=>
BxPC-3	MYXGeY5kfGmxbjDBd5NigQ>?	MX61JO69VQ>?	MoL1NlQhcA>?	NHnMTIFFVVOR	NEGwc2RKdmS3Y3XzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>?	NUOz[Ws2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|IzOjVpPkK1OlMzOjJ3PD;hQi=>
SKOV3	NYnSfmd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvLNVAxKM7:TR?=	M2TzXVI1KGh?	M363cmROW09?	M2KyWmlEPTB;MkCuOFgh\|ryP	NUm4XoF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlQ4PTBpPkK1OlI1PzVyPD;hQi=>
OVCAR4	MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLlbFcxOTByIN88US=>	Mo\yNlQhcA>?	M2XYbGROW09?	NVPi[GtjUUN3ME2yNk4yOyEQvF2=	NYPTVW5xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlQ4PTBpPkK1OlI1PzVyPD;hQi=>
SKOV3	Mof0SpVv[3Srb36gRZN{[Xl?	NF76SI82KM7:TR?=	M{TublczKGh?	NXjOTVlpTE2VTx?=	MmrWTY5lfWOnczDHNk9OKGG{cnXzeC=>	M2HMS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK0O\|UxLz5{NU[yOFc2ODxxYU6=
OVCAR4	NFOzdmNHfW6ldHnvckBCe3OjeR?=	MYm1JO69VQ>?	NEGye2c4OiCq	NGfGPItFVVOR	NF;IcWRKdmS3Y3XzJGczN01iYYLy[ZN1	Mkm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkS3OVAoRjJ3NkK0O\|UxRC:jPh?=
SKOV3	MYrBdI9xfG:\|aYOgRZN{[Xl?	M4LWfVUh\|ryP	MlfBNlQhcA>?	MW\EUXNQ	Mn\5TY5lfWOnczDhdI9xfG:\|aYO=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NEe1NEc,OjV4MkS3OVA9N2F-
OVCAR4	NYD2fpVxSXCxcITvd4l{KEG\|c3H5	MoO2OUDPxE1?	NGXZPI0zPCCq	NInlXJlFVVOR	MX;JcoR2[2W\|IHHwc5B1d3Orcx?=	NXiz[5d{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlQ4PTBpPkK1OlI1PzVyPD;hQi=>
AGS	NFS4bGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrjcYFJOjVizszN	M2DRWFI1KGh?	M4HKU2ROW09?	MX;JR\|UxRTF7LkC5JO69VQ>?	M13oUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkC5PVI{Lz5{NU[wPVkzOzxxYU6=
NCI-N78	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2f5UlI2KM7:TR?=	NVnn[FNOOjRiaB?=	NGXHVWJFVVOR	MUXJR\|UxRTJ4LkOzJO69VQ>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZyOUmyN{c,OjV4MEm5NlM9N2F-
AGS	MXTBdI9xfG:\|aYOgRZN{[Xl?	NIfPOYQ2KM7:TR?=	NWrrUG9jOjRiaB?=	NVLBWYY{TE2VTx?=	M2THe2lv\HWlZYOgZZBweHSxc3nz	M2m2ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkC5PVI{Lz5{NU[wPVkzOzxxYU6=
NCI-N78	M1XvbmFxd3C2b4Ppd{BCe3OjeR?=	NIPDOYY2KM7:TR?=	M4r1VFI1KGh?	MXzEUXNQ	MVnJcoR2[2W\|IHHwc5B1d3Orcx?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZyOUmyN{c,OjV4MEm5NlM9N2F-
AGS	MnzOSpVv[3Srb36gRZN{[Xl?	M2TOfVUh\|ryP	MWWyOEBp	MUDEUXNQ	MUjJcoR2[2W\|IITo[UBifXSxcHjh[5k>	NXrlPVhQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NFk6OjNpPkK1OlA6QTJ\|PD;hQi=>
NCI-N78	NIfpTHBHfW6ldHnvckBCe3OjeR?=	NE[0SJg2KM7:TR?=	NEf0W2UzPCCq	MUXEUXNQ	NVz3OpFoUW6mdXPld{B1cGViYYX0c5Bp[We7	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZyOUmyN{c,OjV4MEm5NlM9N2F-
HSC-3	NEjlVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILzdGIyKM7:TR?=	MVq0PEBp		MYXJR\|UxRTBwNUSg{txO	MlnEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|Nk[xOFMoRjJ3M{[2NVQ{RC:jPh?=
GB30	Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1:1U\|Eh\|ryP	NGWwV3U4KGR?	Mn3oSG1UVw>?	MVvJR\|UxRTBwMEGxJO69VQ>?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyNkSyPEc,OjVzME[0Nlg9N2F-
GB9	NVi0UI84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1SwOlEh\|ryP	MX:3JIQ>	NE[3PGxFVVOR	MoDZTWM2OD1yLkCyOEDPxE1?	M1;se\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUC2OFI5Lz5{NUGwOlQzQDxxYU6=
GB169	NVzzfHFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7vdGYyKM7:TR?=	MV:3JIQ>	NIf5bGhFVVOR	NEHF[IVKSzVyPUCuNFMzKM7:TR?=	NHLLVFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwOlQzQCd-MkWxNFY1Ojh:L3G+
T24	M{TjTGZ2dmO2aX;uJGF{e2G7	Mn6yNUDPxE1?	NVvNVlM6PDhiaB?=	MoDNSG1UVw>?	M2DwR2lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRyM{[zN{c,OjN2MEO2N\|M9N2F-
RT4	MUXGeY5kfGmxbjDBd5NigQ>?	MknSNUDPxE1?	NUTiTFF7PDhiaB?=	MofwSG1UVw>?	MVnJcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2	NXm1WlhWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzNpPkKzOFA{PjN\|PD;hQi=>
UM-UC-3	NIrqeZpHfW6ldHnvckBCe3OjeR?=	M3LHbVEh\|ryP	M2PM[lQ5KGh?	NXjWW\|NtTE2VTx?=	M13pd2lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S=	M3q3WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NECzOlM{Lz5{M{SwN\|Y{OzxxYU6=
T24	NFzSW4VCeG:ydH;zbZMhSXO\|YYm=	MYezMlE3KM7:TR?=	MlP0PVYhcA>?	NWflbZRTTE2VTx?=	Mni1TWM2OD1yLkCzNFYh\|ryP	M2m4[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NECzOlM{Lz5{M{SwN\|Y{OzxxYU6=
RT4	M3S3dGFxd3C2b4Ppd{BCe3OjeR?=	Mn7iN{4yPiEQvF2=	NW\M[4xDQTZiaB?=	Mn7BSG1UVw>?	NIDXOmxKSzVyPUCuNVE6QCEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRyM{[zN{c,OjN2MEO2N\|M9N2F-
UM-UC-3	M3vlTGFxd3C2b4Ppd{BCe3OjeR?=	MojzN{4yPiEQvF2=	NHfsVWg6PiCq	NW\ofmZOTE2VTx?=	MmrkTWM2OD1yLkC0OFkh\|ryP	NXn4doNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzNpPkKzOFA{PjN\|PD;hQi=>
OVCAR-5	NHvlfHJHfW6ldHnvckBCe3OjeR?=	M2G4XVUxKG6P			NITXN3FKdmirYnn0d{Bk\WyuIH3p[5JifGmxbh?=	NIntbIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OzOFMzPyd-MkOzN\|Q{Ojd:L3G+
SKOV3ip2	Ml;nSpVv[3Srb36gRZN{[Xl?	MYS1NEBvVQ>?			M3zkdGlvcGmkaYTzJINmdGxibXnndoF1cW:w	NUi3UnF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzN\|Q{OjdpPkKzN\|M1OzJ5PD;hQi=>
S462	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PiTFExOCEQvF2=	MmLMO\|IhcA>?	MnjvSG1UVw>?	M4LEfWF1fGWwdXH0[ZMh[2WubDDndo94fGh?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN{OEGxOEc,OjN\|MkixNVQ9N2F-
2884	MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{L0WFExOCEQvF2=	MWG3NkBp	MX7EUXNQ	MVLBeJRmdnWjdHXzJINmdGxiZ4Lve5Rp	MnyzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MkixNVQoRjJ\|M{K4NVE1RC:jPh?=
2885	NVrLNGh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nNTlExOCEQvF2=	MonaO\|IhcA>?	NXr2RmY3TE2VTx?=	NIj2ZVJCfHSnboXheIV{KGOnbHyg[5Jwf3Sq	M17ucFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{K4NVE1Lz5{M{OyPFEyPDxxYU6=
CRL-2396	M3XrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHYNVAxKM7:TR?=		MX\3ZZRmeg>?	NH61TldKSzVyPUCuNFkzKM7:TR?=	MlnSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNUO1NlQoRjJ\|MUWzOVI1RC:jPh?=
TIB-48	M1H4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUWxNFAh\|ryP		M2H0VZdifGW{	MmPkTWM2OD1yLkC4PEDPxE1?	Ml;jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNUO1NlQoRjJ\|MUWzOVI1RC:jPh?=
CRL-2396	MlHqR5l1d3SxeHnjJGF{e2G7	M12yUFEh\|ryP	NYjCOJJ{PDhiaB?=	M1HWb5difGW{	M3HKWWlv\HWlZYOgZZBweHSxc3nz	NXy0cWtqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOVM2OjRpPkKzNVU{PTJ2PD;hQi=>
TIB-48	MlvNR5l1d3SxeHnjJGF{e2G7	MVexJO69VQ>?	NF7kb5Y1QCCq	MkPje4F1\XJ?	MX\JcoR2[2W\|IHHwc5B1d3Orcx?=	NUnafXdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOVM2OjRpPkKzNVU{PTJ2PD;hQi=>
AGS	NEDDZWxEgXSxdH;4bYMhSXO\|YYm=	MlXFNE42KM7:TR?=	NIfMXIozPCCq	NVHKVIxVTE2VTx?=	NYTlR3V2TGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy=	NWPkXHZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5O\|I3OTFpPkKyPVczPjFzPD;hQi=>
FLO-1	MVzDfZRwfG:6aXOgRZN{[Xl?	MmqxNE42KM7:TR?=	NWLqXYVOOjRiaB?=	NFm2WWpFVVOR	NYXGcXpLTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl5Mk[xNUc,OjJ7N{K2NVE9N2F-
OE33	NHnGXnVEgXSxdH;4bYMhSXO\|YYm=	NELpZnkxNjVizszN	M3i1PVI1KGh?	NHPWbWFFVVOR	MnrGSIVkemWjc3XzJINmdGxic4Xyeol3[Wx?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl5Mk[xNUc,OjJ7N{K2NVE9N2F-
SKLMS	M{LKe2N6fG:2b4jpZ{BCe3OjeR?=	NE\tdJU4PSCwTR?=	NWfGdXl{QTZiaB?=		MkjvTY5lfWOnczDhdI9xfG:\|aYO=	NV;W[JFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlE6QTdpPkKyPFIyQTl5PD;hQi=>
Leio285	NXvMO49SS3m2b4TvfIlkKEG\|c3H5	M4nwZVc2KG6P	NV;uVWt[QTZiaB?=		NWL1PGpxUW6mdXPld{BieG:ydH;zbZM>	NGG1ZnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyNVk6Pyd-MkK4NlE6QTd:L3G+
Mes-Sa	M33mfGN6fG:2b4jpZ{BCe3OjeR?=	NFPzXJA4PSCwTR?=	NVvRdZNrQTZiaB?=		M{LoPWlv\HWlZYOgZZBweHSxc3nz	Ml20QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MkG5PVcoRjJ{OEKxPVk4RC:jPh?=
DAOY	NELNWYhEgXSxdH;4bYMhSXO\|YYm=	NIq5dWUyOCEQvF2=	MUi3NkBp	M4DBSGROW09?	Ml\2TWM2OD1yLkC0JO69VQ>?	NV:2fWY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2Olk{OzVpPkKyOlY6OzN3PD;hQi=>
IMR32	MWDDfZRwfG:6aXOgRZN{[Xl?	NGXab5YyOCEQvF2=	MXu3NkBp	NXL6VWM1TE2VTx?=	M3TSOmlEPTB;MD6wN{DPxE1?	NVyzPZpFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2Olk{OzVpPkKyOlY6OzN3PD;hQi=>
Molt-4	M{HsbWN6fG:2b4jpZ{BCe3OjeR?=	NX3Kc5B4OTBizszN	MknMO\|IhcA>?	NH7lPYJFVVOR	MYfJR\|UxRTBwMEKg{txO	Mmr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NkmzN\|UoRjJ{Nk[5N\|M2RC:jPh?=
MOLM-13	NIXtRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUi0NHhFOyEQvF2=	MWm3NkBp		NXSzTZpiTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	MknNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEiyOFkoRjJ{NEi4NlQ6RC:jPh?=
HL-60	NH[0WHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XCbFMh\|ryP	MVe3NkBp		M2LrbGRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	Mn23QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEiyOFkoRjJ{NEi4NlQ6RC:jPh?=
MV4-11	M2DsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLDN{DPxE1?	MX[3NkBp		NHfiUlhFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5	NUj0UYd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PFgzPDlpPkKyOFg5OjR7PD;hQi=>
SKM-1	NY\oUW9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\nN{DPxE1?	MmjUO\|IhcA>?		MWLEbY1qdmm\|aHXzJINmdGxidnnhZoltcXS7	MmLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEiyOFkoRjJ{NEi4NlQ6RC:jPh?=
SH2	NX7FflhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFyxOm4{KM7:TR?=	M3\nc\|czKGh?		NYjETmxVTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	M4rlUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEi4NlQ6Lz5{MkS4PFI1QTxxYU6=
NOMO-1	NWriSotsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXRZWtNOyEQvF2=	Mn;sO\|IhcA>?		NWP1SY92TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	NETjVnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
OCL-AML2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fmUFMh\|ryP	NGrQRo04OiCq		M{jEWGRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	M{XI[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEi4NlQ6Lz5{MkS4PFI1QTxxYU6=
PL-21	NWnCSFZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1ra[\|Mh\|ryP	MX23NkBp		MV\EbY1qdmm\|aHXzJINmdGxidnnhZoltcXS7	NGTVbGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
KG-1	M4PQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnqZlc{KM7:TR?=	M4q5[VczKGh?		MVvEbY1qdmm\|aHXzJINmdGxidnnhZoltcXS7	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR6OEK0PUc,OjJ2OEiyOFk9N2F-
A172	MYTDfZRwfG:6aXOgRZN{[Xl?	MlXONVAxKM7:TR?=	M3;0dVI1KGh?	NHXxfGZFVVOR	M{XxSWlEPTB;MD6xNlAh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5NEO5PUc,OjJ{N{SzPVk9N2F-
U87	MVjDfZRwfG:6aXOgRZN{[Xl?	M3nlW\|ExOCEQvF2=	NELDVlczPCCq	NX:zPYVRTE2VTx?=	MnW3TWM2OD1yLkGwOUDPxE1?	NWPsenc{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|Q{QTlpPkKyNlc1Ozl7PD;hQi=>
U251	MnfCR5l1d3SxeHnjJGF{e2G7	NGLCNIEyODBizszN	M2nTSlI1KGh?	NFe4OFFFVVOR	NEnKWmZKSzVyPUCuNVAxKM7:TR?=	NHnLcpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3OFM6QSd-MkKyO\|Q{QTl:L3G+
T98	NYPkb45SS3m2b4TvfIlkKEG\|c3H5	MVixNFAh\|ryP	MWCyOEBp	MkHxSG1UVw>?	MXrJR\|UxRTBwMUK1JO69VQ>?	Mkm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{N{SzPVkoRjJ{Mke0N\|k6RC:jPh?=
LN18	NXn6PYdZS3m2b4TvfIlkKEG\|c3H5	NYTTRYtIOTByIN88US=>	NUDwc3FxOjRiaB?=	NHG4ZYJFVVOR	M3j0VmlEPTB;MD6yNVAh\|ryP	M3nwNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mke0N\|k6Lz5{MkK3OFM6QTxxYU6=
LN443	MkPxR5l1d3SxeHnjJGF{e2G7	M3TrTFExOCEQvF2=	MVSyOEBp	NXy3VnNoTE2VTx?=	NWjNWW95UUN3ME2wMlIzOCEQvF2=	MmfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{N{SzPVkoRjJ{Mke0N\|k6RC:jPh?=
HF66	MV;DfZRwfG:6aXOgRZN{[Xl?	MWGxNFAh\|ryP	NE\NWVIzPCCq	MYnEUXNQ	NHzvT5RKSzVyPUCuNlI2KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5NEO5PUc,OjJ{N{SzPVk9N2F-
HF2303	MYXDfZRwfG:6aXOgRZN{[Xl?	Mn;kNVAxKM7:TR?=	NGrKVYMzPCCq	MnfHSG1UVw>?	NHPGUVhKSzVyPUCuNFYxKM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5NEO5PUc,OjJ{N{SzPVk9N2F-
HF2359	NXL2dINUS3m2b4TvfIlkKEG\|c3H5	M2[0W\|ExOCEQvF2=	NWqxNIxDOjRiaB?=	NWLpOFJ1TE2VTx?=	NGWzd5FKSzVyPUCuNFYxKM7:TR?=	NILzR289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3OFM6QSd-MkKyO\|Q{QTl:L3G+
HF2414	M3TNd2N6fG:2b4jpZ{BCe3OjeR?=	MoHwNVAxKM7:TR?=	MkTHNlQhcA>?	NGHjcZBFVVOR	NX3zW\|JYUUN3ME2wMlA5OCEQvF2=	NFfPR\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3OFM6QSd-MkKyO\|Q{QTl:L3G+
A-673	MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDqR5EyOCEQvF2=	NWS3Vox4QTZiaB?=	NX;IVpZ3TE2VTx?=	NHLsVpVKSzVyPUCuNFMzKM7:TR?=	M1XoVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
TC-32	MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVOxNEDPxE1?	M2jW[Fk3KGh?	M{PlS2ROW09?	MYXJR\|UxRTBwMEO5JO69VQ>?	M3[yT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
TC-71	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHT1fWwyOCEQvF2=	NHG3boM6PiCq	M2TzTGROW09?	NF;qdGNKSzVyPUCuNVAzKM7:TR?=	NXjIN3FURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SK-N-MC	M{nWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzpUlQyOCEQvF2=	NIrneI86PiCq	MV\EUXNQ	M1XsfWlEPTB;MD6wO\|Ih\|ryP	NVKxOW9DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-9	M1P4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zJbFExKM7:TR?=	MkT2PVYhcA>?	MljrSG1UVw>?	M1\PSWlEPTB;MD6wNVgh\|ryP	M1ns[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
CHLA-10	MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moj1NVAh\|ryP	M2TybFk3KGh?	NXTvepVRTE2VTx?=	MoXvTWM2OD1yLkC2NEDPxE1?	Mn;CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
CHLA-25	NWS2SGxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTyb\|UyOCEQvF2=	MmjkPVYhcA>?	MVzEUXNQ	MUPJR\|UxRTBwMU[4JO69VQ>?	NVjj[Vg{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-32	NUnGeYZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljkNVAh\|ryP	M1zWe\|k3KGh?	NXTaUINGTE2VTx?=	Mn7xTWM2OD1yLkGzOkDPxE1?	NIPTO2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
CHLA-56	NIHxS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7uNVAh\|ryP	MWW5OkBp	Ml72SG1UVw>?	NV\1XGs{UUN3ME2xNEDPxE1?	NXuwbWRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-258	MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojRNVAh\|ryP	M{\F[lk3KGh?	NHXtboJFVVOR	MYDJR\|UxRTBwMUOyJO69VQ>?	NX;DcmE3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
COG-E-352	M3vtZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjvXpQyOCEQvF2=	NHjISJc6PiCq	NI\sNW1FVVOR	NGe5ZWJKSzVyPUCuNFQ{KM7:TR?=	Ml;uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
CHLA-90	M1jnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jFPVExKM7:TR?=	MX65OkBp	M3nTOWROW09?	M2K3SmlEPTB;MD6wOlEh\|ryP	NGr3O3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
CHLA-119	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXyxNEDPxE1?	NH;jWYI6PiCq	NUjBfW5oTE2VTx?=	MnnoTWM2OD1yLkCyNkDPxE1?	NXj1e\|FDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
CHLA-122	Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUixNEDPxE1?	MnrlPVYhcA>?	M1zBRmROW09?	MXHJR\|UxRTBwMEG5JO69VQ>?	NHrVR5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
CHLA-136	NWjNVJFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4O2WVExKM7:TR?=	NGXHXpQ6PiCq	MlnBSG1UVw>?	MmjFTWM2OD1yLkCzPUDPxE1?	M4rPRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
CHLA-140	NVzURYR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPtN2JsOTBizszN	NIXIV3I6PiCq	MWXEUXNQ	M4nkSWlEPTB;MD6wNlYh\|ryP	MnLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
LA-N-6	NEO4UXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HQb\|ExKM7:TR?=	M1HlO\|k3KGh?	NEHqSFJFVVOR	NVz4SGVDUUN3ME2wMlA2PCEQvF2=	MlvyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
NB-1643	MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4r4WVExKM7:TR?=	MYq5OkBp	NUX5fFNqTE2VTx?=	NYK0d3RKUUN3ME2wMlA{PyEQvF2=	NIjuN\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
NB-EBc1	NF7CO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonMNVAh\|ryP	NHvX[XU6PiCq	MUjEUXNQ	MUXJR\|UxRTBwMEWwJO69VQ>?	NWXaUlFvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SK-N-BE-1	M2HoUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY[xNEDPxE1?	M3rWO\|k3KGh?	NFrEdJpFVVOR	MXzJR\|UxRTBwMEK4JO69VQ>?	NHHPXlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
SK-N-BE-2	NY[xVlliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPzfWYyOCEQvF2=	NHPERpM6PiCq	NUPYUoRQTE2VTx?=	M{LvdGlEPTB;MD6wN\|Yh\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
SMS-KAN	M1\iRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDPWI4yOCEQvF2=	MVO5OkBp	M1T2cWROW09?	NWD4ZnY{UUN3ME2wMlA{PCEQvF2=	NX;5dZdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-KANR	NWXYc29uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnjfmpIOTBizszN	Mn7EPVYhcA>?	MofOSG1UVw>?	M{jpfWlEPTB;MD6wNlYh\|ryP	NEX6V5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
SMS-KCN	M3zZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PXT\|ExKM7:TR?=	NUjST3RnQTZiaB?=	MVXEUXNQ	NH7pSlhKSzVyPUCuNFE6KM7:TR?=	M4jjd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
SMS-KCNR	M{PEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkP3NVAh\|ryP	MX25OkBp	NGnuUJhFVVOR	Mk\ITWM2OD1yLkCxNEDPxE1?	MnHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
SMS-LHN	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV2xNEDPxE1?	MmrGPVYhcA>?	NI\uVZJFVVOR	NEXvR5VKSzVyPUCuNFMzKM7:TR?=	NVrCVJg2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-MSN	NXrpe3N3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;2cpcyOCEQvF2=	MUe5OkBp	NWPQemJDTE2VTx?=	M2rMcGlEPTB;MD6wNlIh\|ryP	MnzrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
SMS-SAN	NHfsSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYWxNEDPxE1?	MYS5OkBp	Moj5SG1UVw>?	NHrs[W9KSzVyPUCuNFIxKM7:TR?=	NXLVSVVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
Granta-4	NGfNVZhEgXSxdH;4bYMhSXO\|YYm=	M4\FWlExKM7:TR?=	M33EVFch\A>?		MY\JR\|UxRTBwMESwJO69VQ>?	M1PUW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkmxPFY4Lz5{MUK5NVg3PzxxYU6=
DB	MX;DfZRwfG:6aXOgRZN{[Xl?	MWKxNEDPxE1?	MYq3JIQ>		Mm\4TWM2OD1yLkC0NkDPxE1?	M3viTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkmxPFY4Lz5{MUK5NVg3PzxxYU6=
RL	NVK2elJQS3m2b4TvfIlkKEG\|c3H5	NX;KXpl1OTBizszN	NYH0Ro5[PyCm		NYq3VlNyUUN3ME2wMlAyPSEQvF2=	NWrUXJRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyPVE5PjdpPkKxNlkyQDZ5PD;hQi=>
K562	NYfFcnNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXmxNEDPxE1?	MWq5OkBp		MmK2TWM2OD1yLkC4O{DPxE1?	NEC0WFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC5NVY{Oyd-MkGwPVE3OzN:L3G+
LAMA-84	M3j3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfwNVAh\|ryP	M1;vS\|k3KGh?		MYLJR\|UxRTBwMEW3JO69VQ>?	MojDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyOUG2N\|MoRjJzMEmxOlM{RC:jPh?=
MM15	NF7nO5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\VOEDPxE1?	NHzBXIE4OiCq	MnztSG1UVw>?	Moj2TWM2OD1yLkGzJO69VQ>?	Mo\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
OPM1	NXfZO2E{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TRZ\|Qh\|ryP	Mn75O\|IhcA>?	Mlf6SG1UVw>?	NF;DOZBKSzVyPUCuNFMh\|ryP	NY\LVVZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPFI5PDRpPkKwN\|gzQDR2PD;hQi=>
RPM1	NVXqfIRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1roSVQh\|ryP	MVu3NkBp	NVPxUFNtTE2VTx?=	MmrSTWM2OD1zMD6zNkDPxE1?	NVrQPFlpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPFI5PDRpPkKwN\|gzQDR2PD;hQi=>
INA6	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTHOEDPxE1?	M{\UTlczKGh?	NXPLbHlFTE2VTx?=	M1nJRmlEPTB;MD6wNFIh\|ryP	M1vLPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{iyPFQ1Lz5{MEO4Nlg1PDxxYU6=
OPM2	NVi4U3J1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDjV3Y1KM7:TR?=	NW[1eZE6PzJiaB?=	NHPuSGJFVVOR	M2CwVWlEPTB;ND6zO{DPxE1?	MliwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
MM1R	NHrPTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnt[IM1KM7:TR?=	M{mwNVczKGh?	MYHEUXNQ	M3LZcmlEPTB;MT62PEDPxE1?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN6Mki0OEc,OjB\|OEK4OFQ9N2F-
DOX40	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nRdFQh\|ryP	M{XPb\|czKGh?	NICyRnNFVVOR	MX\JR\|UxRTVwNEig{txO	MlPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
LR5	NWHjT2s{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXi0JO69VQ>?	NW\1NFZvPzJiaB?=	NH[zS2xFVVOR	M1vz[WlEPTB;Mj61N{DPxE1?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN6Mki0OEc,OjB\|OEK4OFQ9N2F-
U266	Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDROEDPxE1?	MkLJO\|IhcA>?	NHjoOFNFVVOR	MmLzTWM2OD1zLkSzJO69VQ>?	NVLIVXhiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPFI5PDRpPkKwN\|gzQDR2PD;hQi=>
RD	NHPyOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHITJZVOTBizszN	Mn22PVYhcA>?		NFLSdo9KSzVyPUCuNlI5KM7:TR?=	NUfEbYtTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
Rh41	NVXoXWo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHMWYgyOCEQvF2=	NIC5eGk6PiCq		NFTsPXdKSzVyPUCuNFkxKM7:TR?=	NH7BU2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGwPFM{QCd-MkCxNFg{Ozh:L3G+
Rh30	NHXFVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHi5dokyOCEQvF2=	NWeyfFBrQTZiaB?=		MXrJR\|UxRTBwMkOwJO69VQ>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
BT-12	MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYKxNEDPxE1?	M2DoV\|k3KGh?		MXfJR\|UxRTBwME[wJO69VQ>?	NFXLcWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGwPFM{QCd-MkCxNFg{Ozh:L3G+
CHLA-266	M4Dhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{T6VVExKM7:TR?=	MVy5OkBp		Mlu1TWM2OD1yLkC3NkDPxE1?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
TC-71	NVXNN3dlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33rT\|ExKM7:TR?=	NEe4R4I6PiCq		Ml;1TWM2OD1yLkGwNkDPxE1?	M3zZcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
SJ-GBM2	MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\iVVUyOCEQvF2=	NVHxZ\|RbQTZiaB?=		MnP0TWM2OD1yLkC1NEDPxE1?	MnvXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
NALM-6	MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfJNVAh\|ryP	M3O4eVk3KGh?		NXnQTox7UUN3ME2wMlA3OiEQvF2=	M3L1W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
COG-LL-317	M37hVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLzcpBIOTBizszN	MmnIPVYhcA>?		MojNTWM2OD1yLkC0O{DPxE1?	NYnqWGxYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
RS4-11	NFq2emdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVSxNEDPxE1?	NYe1[Gl1QTZiaB?=		MoX1TWM2OD1yLkCxPEDPxE1?	MlLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
MOLT-4	NVf0OHpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTmNVAh\|ryP	NInHW2c6PiCq		NGfxNmRKSzVyPUCuNFI3KM7:TR?=	NVPHeVFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
CCRF-CEM	NIrmTWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWOxNEDPxE1?	Mn23PVYhcA>?		M1;3U2lEPTB;MD6wPVQh\|ryP	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
Kasumi-1	Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\jSIszOTBizszN	NI\1cmg6PiCq		MoL5TWM2OD1yLkGwN{DPxE1?	M2jCbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
Karpas-299	MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHONVAh\|ryP	M4K5Wlk3KGh?		NFW3UotKSzVyPUCuNFM5KM7:TR?=	NVPXfHY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
Ramos-RA1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzrOXpNOTBizszN	NVe3UY43QTZiaB?=		MYfJR\|UxRTBwMUK3JO69VQ>?	NYXZUGV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
GSS	M1rLRmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mlq2O\|IhcHK\|		M3vkc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iR2PTJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6wN\|kh\|ryPLh?=	NVL2dlZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
LU99A	NGXBe\|VCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXO3NkBpenN?		Mnf2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOVUm5RUBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNFYzKM7:TT6=	MnjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkW2NVcoRjJ3NkK1OlE4RC:jPh?=
HL60	NHTXXZRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MlLOO\|IhcHK\|		M1f5OGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNFc1KM7:TT6=	Mn3rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkW2NVcoRjJ3NkK1OlE4RC:jPh?=
LC2/ad	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MkDqO\|IhcHK\|		NGnNN2JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzDNk9i\CClZXzsd{Bi\nSncjC3NkBpenNiYomgW3NVQCCjc4PhfUwhUUN3MDC9JFAvODd5IN88UU4>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
MKN45	M3\qUmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M17OSlczKGi{cx?=		MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2NTkS1JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6wPVMh\|ryPLh?=	NFn5[o49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVYyPyd-MkW2NlU3OTd:L3G+
HCT116	MYnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NWi0TmtIPzJiaILz		MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNFk2KM7:TT6=	M1LiW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1OlE4Lz5{NU[yOVYyPzxxYU6=
Lu116	M2TOfmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1fRflczKGi{cx?=		M2\nWGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTIWxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGfTWFgh[XO\|YYmsJGlEPTBiPTCwMlA6PyEQvF2u	M4KzPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1OlE4Lz5{NU[yOVYyPzxxYU6=
NCI-H358	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mn\mO\|IhcHK\|		Mm[2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFM2QCClZXzsd{Bi\nSncjC3NkBpenNiYomgW3NVQCCjc4PhfUwhUUN3MDC9JFAvOSEQvF2u	M{T0XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1OlE4Lz5{NU[yOVYyPzxxYU6=
MIAPaCa2	NVPQU4tGSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MYG3NkBpenN?		M2npfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVnBVIFE[TJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjF\|IN88UU4>	NIS2fFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVYyPyd-MkW2NlU3OTd:L3G+
PC14	MYTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NHv3d404OiCqcoO=		MnnoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{G0JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6xO{DPxE1w	Mn7IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkW2NVcoRjJ3NkK1OlE4RC:jPh?=
HT-29	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MUe3NkBpenN?		NFPpZ2hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDXV3Q5KGG\|c3H5MEBKSzVyIE2gNE4{OyEQvF2u	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
HCT15	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NF7ER2c4OiCqcoO=		MmHSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxOUBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuO\|Qh\|ryPLh?=	NIjESWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVYyPyd-MkW2NlU3OTd:L3G+
Sf9	NXzOT\|BWTnWwY4Tpc44h[XO\|YYm=				M3\oOGNwdXCndHn0bZZmKGmwaHnibZRqd25ib3[gdoVkd22kaX7hcpQhdW:3c3WgZZVzd3KjIHvpcoF{\SCDIHX4dJJme3OnZDDpckBqdnOnY4SgV4Y6KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIFHUVEwhU2liPTCwMlAxODNizszNMi=>	NYnl[3Z6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNFE2PjRpPkK2NVAyPTZ2PD;hQi=>
Sf9	NYTCelZxTnWwY4Tpc44h[XO\|YYm=				MV\Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IH3veZNmKGG3cn;yZUBscW6jc3WgRUBmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoOTDj[YxteyC3c3nu[{BjcW:2aX6tS2xTWkGVTFegZZMhe3Wkc4TyZZRmKGmwIIDy[ZNmdmOnIH;mJHto[W2vYT2zN3BeSVSSLDDJR\|UxKD1iMD6wNFEh\|ryPLh?=	NIfZd2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGwNVU3PCd-Mk[xNFE2PjR:L3G+
HCT116	NEjxZXRHfW6ldHnvckBie3OjeR?=				NFz1WZhKdmirYnn0bY9vKG:oIHH1do9z[SCtaX7hd4UhSSCjdYTvdIhwe3Cqb4L5cIF1cW:wIHH0JHQzQDhiaX6gbJVu[W5iSFPUNVE3KGOnbHzzJIJ6KGmvbYXuc4ZtfW:{ZYPj[Y5k\SCjbnHsfZNqeyxiSVO1NEA:KDBwMEC3JO69VS5?	NW\TRZJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNFE2PjRpPkK2NVAyPTZ2PD;hQi=>
HCT116	NFXyNFJEgXSxdH;4bYNqfHliYYPzZZk>				NX;OV5U{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHL5JGJz\FViaX7jc5Jxd3KjdHnvckBie3OjeTygS2k2OCB;IECuNFMh\|ryPLh?=	M{nwTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUCxOVY1Lz5{NkGwNVU3PDxxYU6=
HCT116	MoTPSpVv[3Srb36gZZN{[Xl?				MlHJTY5pcWKrdHnvckBw\iCjdYLvdoEhc2mwYYPlJGIhcW5iaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiaHnzeI9v\SCKMzDwbI9{eGixconsZZRqd25iYomgbY1ufW6xZnz1c5Jme2OnbnPlJIFv[Wy7c3nzMEBKSzVyIE2gNU42KM7:TT6=	M{D2clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUCxOVY1Lz5{NkGwNVU3PDxxYU6=
BL21 (DE3) Rosetta	NFS1UmxHfW6ldHnvckBie3OjeR?=		M1LXdVMxKG2rboO=		NWjzb4N3UW6qaXLpeIlwdiCxZjDIbZMufGGpZ3XkJIh2dWGwIFH1do9z[SCDIHvpcoF{\SBqMUKyJJRwKDRyIILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBDVDJzIDjESVMqKFKxc3X0eIEh[2WubIOgeZNqdmdiYnnveIlvgWyjdHXkJHNVUzJic4Xid5Rz[XSnIHnuZ5Vj[XSnZDDmc5IhOzBibXnud{BjgSCKVGLGJIF{e2G7LDDJR\|UxKD1iMD6wNFAxPCEQvF2u	NXXEVFhZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezPVEyOzNpPkK3N\|kyOTN\|PD;hQi=>
HeLa Kyoto	NF3tTZhHfW6ldHnvckBie3OjeR?=		NUG3cnFyOjBiaILz		M{nVO2lvcGmkaYTpc44hd2ZiQYXyc5JiKEJia3nuZZNmKGmwIHj1cYFvKEinTHGgT5lwfG9iY3XscJMh[XO\|ZYPz[YQh[XNiZX\m[YN1KG:wIHTpd5RzcWK3dHnvckBw\iCyaIPwbI8ucGm\|dH;u[UBJOyC\|ZYKxNEBt\X[nbDDpcoN2[mG2ZXSg[o9zKDJyIHjyd{whUUN3MDC9JFAvODBzNTFOwG0v	M1LseFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{mxNVM{Lz5{N{O5NVE{OzxxYU6=
HeLa Kyoto	Moi5SpVv[3Srb36gZZN{[Xl?		NFPHZ\|UzOCCqcoO=		MmHJTY5pcWKrdHnvckBw\iCDdYLvdoEhSSCtaX7hd4Uh[XW2b4Doc5NxcG:{eXzheIlwdiCjdDDUbJIzQDhiaX6gbJVu[W5iSHXMZUBMgW:2bzDj[YxteyCrbnP1ZoF1\WRiZn;yJFIxKGi{czygTWM2OCB;IECuNFA3PyEQvF2u	NW\veWZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezPVEyOzNpPkK3N\|kyOTN\|PD;hQi=>
multiple myeloma	NFOxN29HfW6ldHnvckBie3OjeR?=				NX3xTpgzW3WycILld5Nqd25ib3[gZ4VtdCCvaYTvd4l{KGmwIHj1cYFvKG23bITpdIxmKG27ZXzvcYEh[2WubIOsJGlEPTBiPTCwMlAxOyEQvF2u	M3vXSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUG4NFk3Lz5{OEmxPFA6PjxxYU6=
Calu6	NVHTOohLSW62aYT1cY9zKGG\|c3H5	M4nTWlIxKG2pL3vn	M4qybVIyKGSjeYO=		NXu2eJhpSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gR4FtfTZiY3XscJMhgGWwb3fyZYZ1\WRiaX6gcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JiZ4Lve5RpKGmwaHnibZRqd25iYYSgNlAhdWdxa3esJJBwKGKrZDDh[I1qdmm\|dHXy[YQh\m:{IEKxJIRigXN?	NYjoVJR3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNFE2PjRpPkK2NVAyPTZ2PD;hQi=>
HeLa Kyoto	M{j6dmZ2dmO2aX;uJIF{e2G7	M{LqcVAvOjVidV2=	MYSyNEBpenN?		NYL4N3oxUW6qaXLpeIlwdiCxZjDBeZJwemFiQTDrbY5ie2VibH;jZYxqgmG2aX;uJIF1KHOyaX7kcIUhdWmlcn;0eYJ2dGW\|IHnuJIh2dWGwIFjlUIEhU3mxdH:gZ4VtdHNiYYSgNE4zPSC3TTDpcoN2[mG2ZXSg[o9zKDJyIHjydy=>	NGjubm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O5NVE{Oyd-MkezPVEyOzN:L3G+
MDA-MB-231	NEXaeIxHfW6ldHnvckBie3OjeR?=	Mn;3NUB2VQ>?	NYXrclVwPDhiaILz		NH2wflJKdmS3Y4Tpc44hd2ZiY3jyc41we2:vZTDhcIlodm2nboSg[IVn\WO2czDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KESDUFmgd5RicW6rbnegZoF{\WRiaX3teY5w\my3b4Lld4NmdmOnIHHzd4F6	M4PiNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7M{W4NVQ4Lz5{OUO1PFE1PzxxYU6=
MDA-MB-231	NF7yfWFHfW6ldHnvckBie3OjeR?=	M4[yfFEhfU1?	NILtOZo1QCCqcoO=		NE\j[YhKdmS3Y4Tpc44hd2ZiYXLldpJidnRic4DpcoRt\SCob4LtZZRqd25id3n0bEB1emmyb3zhdkBidmRidHX0doFxd2yjcjDvZ4N2enKnbnPlJIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZQhOSC3TTDh[pRmeiB2ODDodpMh[nliRFHQTUB{fGGrbnnu[{Bj[XOnZDDpcY12dm:obIXvdoV{[2WwY3WgZZN{[Xl?	NVPFZplURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzOVgyPDdpPkK5N\|U5OTR5PD;hQi=>
MDA-MB-231	NXnvXHVqTnWwY4Tpc44h[XO\|YYm=	MXOwMlUhfU1?	MlTsOFghcHK\|		NWT0b4ZEUW6qaXLpeIlwdiCxZjDhcJBp[S22dXL1cIlvKGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO\|ZYPz[YQh[XNiYXLvcIl{cG2nboSgc4YhemWpdXzhdkBtd2OjdHnvckBw\iCycn;0[YlvKGG2IECuOUB2VSCjZoTldkA1QCCqcoOgZpkhTEGSSTDzeIFqdmmwZzDiZZNm\CCrbX31co9ndHWxcnXzZ4Vv[2ViYYPzZZk>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN3OEG0O{c,Ojl\|NUixOFc9N2F-
MDA-MB-231	NIfQc5FHfW6ldHnvckBie3OjeR?=	NU\KPXYxOC53IIXN	M{f1ZlQ5KGi{cx?=		MULJcohq[mm2aX;uJI9nKEGXUlvBJIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZN{\XO\|ZXSgZZMh[WKxbHnzbI1mdnRib3[gdoVofWyjcjDsc4NifGmxbjDv[kBxem:2ZXnuJIF1KDBwNTD1UUBi\nSncjC0PEBpenNiYomgSGFRUSC\|dHHpcolv\yCkYYPl[EBqdW23bn;mcJVwemW\|Y3XuZ4Uh[XO\|YYm=	NULnbYJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzOVgyPDdpPkK5N\|U5OTR5PD;hQi=>
TC32	M1jrRZFJXFNiYYPzZZk>				NILP[XRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	NYfyRmtwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	NVzKTlFFeUiWUzDhd5NigQ>?				NV\Fc2pMeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	M1[xPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	M4nYZZFJXFNiYYPzZZk>				M4rBWpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	NYq2NnFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	MWjxTHRUKGG\|c3H5				NYPNcZl3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	M1Hvd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	MUXxTHRUKGG\|c3H5				MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	M1rPVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	MX3xTHRUKGG\|c3H5				MmPFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>?	MoHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	MXnxTHRUKGG\|c3H5				MlrXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUWchPjNiKE[tWGchWiliY3XscJM>	NU\i[\|RRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS	MlO5dWhVWyCjc4PhfS=>				Mki5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWU0zKE:VIHPlcIx{	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	Mnj1dWhVWyCjc4PhfS=>				NImyVnNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	Mk[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NXfLV5ZJeUiWUzDhd5NigQ>?				MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NFOyOoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	M4[zZ5FJXFNiYYPzZZk>				MlLNdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	NXjIZm45RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	MVvxTHRUKGG\|c3H5				MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	NYPUdmtZeUiWUzDhd5NigQ>?				MmDMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	NGDXPFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NF7PNppyUFSVIHHzd4F6				M1z5dpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN?	M3nlWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	MkDmdWhVWyCjc4PhfS=>				M3rsSpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	Mm\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	NYX1[IJteUiWUzDhd5NigQ>?				NEKzOlNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBU[W:\|LUKgZ4VtdHN?	NUPWOZZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AURKA(T288) / p-EIF4E(S209) / c-Myc; PubMed: 28073841 Clin Cancer Res Inhibition of AURKA with alisertib downregulated p-EIF4E (S209) and c-MYC protein levels as assayed by Western blotting. phospho-Aurora A / Aurora B; PubMed: 22863010 Cell MLN8237differentially inhibited phosphorylation of Aurora kinases. CMK cells were incubated with 0.1 µM paclitaxel for 18 hr, then DMSO or MLN8237 was added and incubated for 2 hr. The degree of phosphorylation of the Aurora kinases in each sample was determined by Western blot. H3S10P / H3K27me2 / H3K27me3 / H3K9me2 / H3AcK / H4K16Ac; PubMed: 29477140 Mol Cells THP-1 cells were treated with alisertib or DMSO for 48 h. The levels of histone modifications were detected by western blot analysis with the indicated antibodies. H3 was used as a loading control.	28073841 22863010 29477140
Growth inhibition assay	Cell viability; PubMed: 25632225 Drug Des Devel Ther PANC-1 and BxPC-3 cells were treated with ALS at concentrations ranging from 0.1 μM to 50 μM for 24 hours. The viability of PANC-1 and BxPC-3 cells determined by MTT assay. ALS, alisertib.	25632225
Immunofluorescence	acetylated α-tubulin / γ-tubulin; PubMed: 29401581 FASEB J Representative immunofluorescence (IF) image and graph in human PKD1-mutant WT9-7, WT9-12 cells or hTERT-RPE1 (RPE1) cells after 2 hours treatment with vehicle, ganetespib , or alisertib to inhibit AURKA, or combination of alisertib and ganetespib. acetylated α-tubulin (red); γ-tubulin (green); DAPI (blue). Scale bars, 5 μm. E-cadherin / β-catenin / vimentin / p-SMAD5; PubMed: 23334326 Oncogene Immunofluorescence analysis of CD24 (-/low) cells treated with1 μM MLN8237 for 48 and 72 h showing reversion of EMT. E-cadherin and p-SMAD5 were labeled in red, β-catenin and vimentin were labeled in green, and DNA was labeled in blue with Hoechst dye. Centrin-2 / tubulin; PubMed: 30899434 Oncotarget Following inhibition of Aurora A kinase activity with 100 nM alisertib, cells with two or excess centrosomes similarly exhibit disorganized mitotic spindles. Cells with extra centrosomes are efficiently clustered into bipolar spindles prior to anaphase onset while those with supernumerary centrosomes undergo multipolar mitoses. Centrin-2, a marker of centrioles is shown in green, tubulin in red, and chromatin in blue. AurA inhibitor: alisertib. phospho-Aurora A(T288); PubMed: 20382844 Blood MM1.S cells were treated with DMSO or MLN8237 (0.5μM) for 24 hours and then stained with anti-phospho (Thr288)-Aurora-A kinase antibody (red), αtubulin (green), and DNA (blue). Overlapping localization is shown in the merged images. Arrow indicates Aurora-A autophosphorylation on Thr288 in the centrosome (original magnification ×40). Magnified single mitotic cell image is shown in the right panel.	29401581 23334326 30899434 20382844

体内研究

MLN8237口服处理，显著降低肿瘤负担，按15 mg/kg 和30 mg/kg剂量处理肿瘤生长抑制率(TGI) 分别为42%和80%,且与对照组相比，延迟小鼠寿命。^[2] MLN8237 (30 mg/kg) 与Cisplatin (2 mg/kg) 联用作用于FLO-1移植瘤，与单独用药相比，抗癌活性增强，伴随着Ki-67表达受抑制，细胞核p73蛋白和cleaved caspase 3表达增强。^[3]

激酶实验：^[1]	- 合并 Aurora A放射性闪光板酶实验: 进行Aurora A放射性闪光板酶实验，测定体外MLN8237抑制程度。在Sf9细胞中表达重组Aurora A，然后使用GST亲和层析进行纯化。Aurora A 肽底物与生物素联合形成生物素-GLRRASLG。在50 mM Hepes (pH 7.5), 10 mM MgCl₂, 5 mM DTT, 0.05% Tween-20, 2 μM 肽底物, 3.3 μCi/mL [γ-³³ P]ATP 2 μM, 和浓度不断增高的MLN8237 的混合物中进行Aurora A激酶 (5 nM)实验。
细胞实验：^[2]	- 合并 Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, 和U266 Concentrations: 溶于DMSO,终浓度为~10 μM Incubation Time: 24, 48, 和72小时 Method: 使用不同浓度MLN8237处理细胞24, 48,和72小时。通过MTT实验测定细胞活力，通过测定 3[³H]-胸甘渗透而测定细胞增殖。为了分析细胞周期，使用70%乙醇在-20^oC下使细胞通透，然后与50 μg/mL PI 和20 单位/mL RNase-A温育。通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件分析DNA含量。为了测定凋亡和衰老，使用异硫氰酸荧光素-annexin V和PI对细胞进行染色。通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件测定凋亡细胞。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: 皮下接种 MM1.S 细胞的SCID鼠 Dosages: ~30 mg/kg/day Administration: 口服处理 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	27 mg/mL (52.03 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+30% PEG300+5%Tween-80+ddH2O	6mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Alisertib (MLN8237) SDF

分子量	518.92
化学式	C₂₇H₂₀ClFN₄O₄
CAS号	1028486-01-2
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04479306	Recruiting	Drug: Alisertib\|Drug: Osimertinib\|Drug: Sapanisertib	Recurrent Lung Non-Small Cell Carcinoma\|Stage IIIB Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	M.D. Anderson Cancer Center	June 18 2020	Phase 1
NCT02812056	Withdrawn	Drug: Alisertib\|Drug: TAK-228	Malignant Neoplasms of Digestive Organs\|Malignant Neoplasms of Female Genital Organs\|Malignant Neoplasms of Lip Oral Cavity and Pharynx\|Malignant Neoplasms of Male Genital Organs	M.D. Anderson Cancer Center\|Millennium Pharmaceuticals Inc.	September 2016	Phase 1
NCT02719691	Completed	Drug: Alisertib\|Drug: MLN0128	Metastatic Breast Cancer\|Solid Tumors	University of Colorado Denver	May 13 2016	Phase 1
NCT02367352	Terminated	Drug: Alisertib\|Drug: Paclitaxel	Advanced Solid Tumors\|Ovarian Cancer\|Small Cell Lung Cancer	Millennium Pharmaceuticals Inc.\|Takeda	March 19 2015	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What is the suggested formulation of this compound for mouse injection(i.p.)?
回答：
It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

泛Aurora Kinase抑制剂

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
泛Aurora Kinase抑制剂

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
活性最高的Aurora Kinase抑制剂

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
用于临床的Aurora Kinase抑制剂

VX-680 (Tozasertib, MK-0457) : Phase II for Advanced Non-Small Cell Lung Cancer (NSCLC).
经典的Aurora Kinase抑制剂

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

研究领域

产品类型

定制您的化合物库

Alisertib (MLN8237)

客户使用Selleck生产的Alisertib (MLN8237)发表文献277篇：

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Alisertib (MLN8237) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

常见问题及建议解决方法

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

相关Aurora Kinase产品